2013-09-25 15:12:42 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Celldex Therapeutics, Inc. (CLDX) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Celldex Therapeutics, Inc. (CLDX). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Celldex Therapeutics, Inc. investor.
Report Summary: Celldex Therapeutics, Inc. is a below average quality company with a positive outlook. Celldex Therapeutics, Inc. has weak business growth and is run by inefficient management. The trend in Celldex Therapeutics, Inc. fair value exchange rate against its closest rated-competitor, Genetic Technologies Limited (ADR), has been appreciating over the past 2 weeks. When compared to its closest competitor, Celldex Therapeutics, Inc. shows similar undervaluation and is equally likely to outperform the market.
The report breaks down the Total StockMark into
its three components - business, management and price, performing an in-depth analysis of Celldex Therapeutics, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.